

# Philippe Mathurin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8831067/publications.pdf>

Version: 2024-02-01

377  
papers

38,278  
citations

3325

91  
h-index

2940

189  
g-index

401  
all docs

401  
docs citations

401  
times ranked

24081  
citing authors

#	ARTICLE	IF	CITATIONS
1	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1195-1206.	13.9	2,352
2	Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.	13.9	1,466
3	Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2009, 360, 1839-1850.	13.9	1,004
4	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.	13.9	945
5	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor $\alpha$ and $\beta$ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	0.6	847
6	Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2009, 360, 2758-2769.	13.9	799
7	Early Liver Transplantation for Severe Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2011, 365, 1790-1800.	13.9	792
8	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014, 370, 1993-2001.	13.9	752
9	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2608-2617.	13.9	740
10	Alcoholic liver disease. <i>Nature Reviews Disease Primers</i> , 2018, 4, 16.	18.1	660
11	Alcoholic liver disease: mechanisms of injury and targeted treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 231-242.	8.2	643
12	Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. <i>Gastroenterology</i> , 2015, 149, 379-388.	0.6	608
13	EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. <i>Journal of Hepatology</i> , 2012, 57, 399-420.	1.8	602
14	The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. <i>Hepatology</i> , 2007, 45, 1348-1354.	3.6	598
15	EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. <i>Journal of Hepatology</i> , 2018, 69, 154-181.	1.8	591
16	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3509-3516.	0.8	544
17	Impact of hepatitis B and C virus on kidney transplantation outcome. <i>Hepatology</i> , 1999, 29, 257-263.	3.6	521
18	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019, 575, 505-511.	13.7	493

#	ARTICLE	IF	CITATIONS
19	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. <i>New England Journal of Medicine</i> , 2017, 376, 2134-2146.	13.9	467
20	Determination of reliability criteria for liver stiffness evaluation by transient elastography. <i>Hepatology</i> , 2013, 57, 1182-1191.	3.6	466
21	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. <i>Hepatology</i> , 2010, 51, 210-218.	3.6	458
22	A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis. <i>New England Journal of Medicine</i> , 1995, 332, 1457-1463.	13.9	452
23	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. <i>Hepatology</i> , 2013, 57, 1153-1162.	3.6	452
24	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019, 393, 1453-1464.	6.3	449
25	Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease. <i>Gastroenterology</i> , 2009, 137, 532-540.	0.6	440
26	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. <i>Annals of Internal Medicine</i> , 2009, 151, 167.	2.0	422
27	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. <i>Gastroenterology</i> , 2017, 152, 142-156.e2.	0.6	420
28	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	1.8	401
29	Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. <i>Gastroenterology</i> , 2016, 150, 785-790.	0.6	387
30	A Randomized Trial of Prednisolone in Patients with Severe Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 1992, 326, 507-512.	13.9	376
31	A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. <i>Hepatology</i> , 2004, 39, 1390-1397.	3.6	371
32	Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. <i>Gut</i> , 2011, 60, 255-260.	6.1	363
33	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	0.6	353
34	Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. <i>Gastroenterology</i> , 2017, 152, 157-163.	0.6	324
35	Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. <i>Journal of Hepatology</i> , 2002, 36, 480-487.	1.8	319
36	Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. <i>Gastroenterology</i> , 2020, 159, 1290-1301.e5.	0.6	310

#	ARTICLE	IF	CITATIONS
37	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. <i>Hepatology</i> , 2011, 54, 1987-1997.	3.6	309
38	Infection in Patients With Severe Alcoholic Hepatitis Treated With Steroids: Early Response to Therapy Is the Key Factor. <i>Gastroenterology</i> , 2009, 137, 541-548.	0.6	305
39	Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. <i>Hepatology</i> , 1998, 27, 868-872.	3.6	286
40	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	5.1	285
41	A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2011, 54, 1011-1019.	1.8	278
42	Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. <i>Journal of Hepatology</i> , 2017, 67, 708-715.	1.8	276
43	Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. <i>Gastroenterology</i> , 1996, 110, 1847-1853.	0.6	267
44	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). <i>Lancet Infectious Diseases</i> , The, 2015, 15, 397-404.	4.6	267
45	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. <i>Hepatology</i> , 2008, 47, 1604-1614.	3.6	266
46	Exacerbation of Alcoholic Liver Injury by Enteral Endotoxin in Rats. <i>Hepatology</i> , 2000, 32, 1008-1017.	3.6	256
47	Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. <i>Gastroenterology</i> , 1999, 116, 378-386.	0.6	255
48	Trends in the management and burden of alcoholic liver disease. <i>Journal of Hepatology</i> , 2015, 62, S38-S46.	1.8	254
49	Albumin Dialysis With a Noncell Artificial Liver Support Device in Patients With Acute Liver Failure. <i>Annals of Internal Medicine</i> , 2013, 159, 522.	2.0	231
50	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015, 62, 762-772.	3.6	230
51	Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease. <i>Annals of Surgery</i> , 2014, 260, 893-899.	2.1	204
52	Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. <i>Gastroenterology</i> , 2005, 128, 334-342.	0.6	194
53	Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. <i>Hepatology</i> , 2014, 59, 2170-2177.	3.6	193
54	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. <i>Gastroenterology</i> , 2018, 155, 1436-1450.e6.	0.6	183

#	ARTICLE	IF	CITATIONS
55	In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features.. Journal of Clinical Pathology, 1997, 50, 401-406.	1.0	181
56	Prednisolone With vs Without Pentoxifylline and Survival of Patients With Severe Alcoholic Hepatitis. JAMA - Journal of the American Medical Association, 2013, 310, 1033.	3.8	181
57	Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. Gastroenterology, 2012, 143, 608-618.e5.	0.6	179
58	Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placeboâ€”a Meta-analysis of Individual Data From Controlled Trials. Gastroenterology, 2018, 155, 458-468.e8.	0.6	153
59	Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. Gastroenterology, 2014, 146, 1240-1248.	0.6	151
60	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology, 2020, 71, 522-538.	3.6	151
61	Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. Hepatology, 2017, 66, 1464-1473.	3.6	149
62	Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. Journal of Hepatology, 2008, 48, 465-470.	1.8	148
63	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	1.8	144
64	Diagnosis and Treatment of Alcohol-Associated Liver Disease. JAMA - Journal of the American Medical Association, 2021, 326, 165.	3.8	144
65	Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut, 2015, 64, 1949-1960.	6.1	137
66	The Evolution of Severe Steatosis After Bariatric Surgery Is Related to Insulin Resistance. Gastroenterology, 2006, 130, 1617-1624.	0.6	136
67	Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology, 2007, 45, 1275-1281.	3.6	136
68	Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis. Gastroenterology, 2015, 149, 398-406.e8.	0.6	134
69	Effect of terlipressin (GlypressinÂ®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study*. European Journal of Gastroenterology and Hepatology, 2002, 14, 153-158.	0.8	131
70	Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. British Journal of Surgery, 2012, 99, 855-863.	0.1	130
71	Prospective analysis of aneurysm treatment in a series of 103 consecutive patients when endovascular embolization is considered the first option. Journal of Neurosurgery, 2000, 93, 175-182.	0.9	127
72	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nature Communications, 2019, 10, 3126.	5.8	124

#	ARTICLE	IF	CITATIONS
73	Ethanol Sclerotherapy of Venous Malformations: Evaluation of Systemic Ethanol Contamination. <i>Journal of Vascular and Interventional Radiology</i> , 2001, 12, 595-600.	0.2	123
74	Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1047-1054.	1.9	123
75	Recurrent Alcoholic Cirrhosis In Severe Alcoholic Relapse After Liver Transplantation: A Frequent and Serious Complication. <i>American Journal of Gastroenterology</i> , 2015, 110, 1160-1166.	0.2	121
76	Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data. <i>PLoS ONE</i> , 2012, 7, e30325.	1.1	117
77	Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. <i>Journal of Hepatology</i> , 2000, 32, 579-586.	1.8	114
78	Impact of Impaired Aerobic Capacity on Liver Transplant Candidates. <i>Transplantation</i> , 2008, 86, 1077-1083.	0.5	114
79	Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. <i>Liver International</i> , 2005, 25, 349-356.	1.9	113
80	Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. <i>Hepatology</i> , 2012, 55, 58-67.	3.6	112
81	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020, 69, 764-780.	6.1	112
82	Effect of binge drinking on the liver: an alarming public health issue?. <i>Gut</i> , 2009, 58, 613-617.	6.1	111
83	Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. <i>Hepatology</i> , 2003, 38, 1363-1369.	3.6	110
84	Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14.	0.6	107
85	Management of alcoholic hepatitis. <i>Journal of Hepatology</i> , 2012, 56, S39-S45.	1.8	103
86	Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1193-1201.	1.9	102
87	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	1.8	100
88	Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. <i>Gastroenterology</i> , 2019, 156, 997-1009.e5.	0.6	100
89	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir) Tj ETQq1 1 0.784314 rgBT /Oyerlock 10	3.6	96
90	Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. <i>Journal of Hepatology</i> , 1997, 26, 312-324.	1.8	93

#	ARTICLE	IF	CITATIONS
91	Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2108-2120.	1.3	92
92	ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. <i>Journal of Hepatology</i> , 2013, 59, 805-813.	1.8	89
93	Consensus conference: Indications for Liver Transplantation, January 19 and 20, 2005, Lyon-Palais Des Congrès. <i>Liver Transplantation</i> , 2006, 12, 998-1011.	1.3	88
94	Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. <i>Lancet, The</i> , 1998, 351, 1930-1931.	6.3	83
95	Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 499-506.	0.8	82
96	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. <i>Gastroenterology</i> , 2018, 155, 431-442.e10.	0.6	81
97	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2020, 73, 1046-1062.	1.8	79
98	Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. <i>European Radiology</i> , 1999, 9, 128-136.	2.3	78
99	A Multidimensional Case-Control Study of Dietary, Alcohol, and Tobacco Habits in Alcoholic Men with Chronic Pancreatitis. <i>Pancreas</i> , 1995, 10, 231-238.	0.5	77
100	Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis. <i>Journal of Hepatology</i> , 2011, 55, 1187-1194.	1.8	77
101	1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY. <i>Journal of Hepatology</i> , 2012, 56, S549.	1.8	76
102	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). <i>Hepatology</i> , 2016, 64, 1136-1147.	3.6	75
103	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	3.6	74
104	Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. <i>Glycobiology</i> , 2006, 16, 281-293.	1.3	72
105	Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. <i>Journal of Hepatology</i> , 2019, 70, 521-530.	1.8	72
106	Perspectives on Treatment for Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2016, 150, 1835-1848.	0.6	71
107	Hepatorenal syndrome. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1054-1056.	1.1	69
108	Surgical Clipping May Lead to Better Results than Coil Embolization: Results from a Series of 101 Consecutive Unruptured Intracranial Aneurysms. <i>Neurosurgery</i> , 2003, 52, 1280-1290.	0.6	69

#	ARTICLE	IF	CITATIONS
109	Ischemic hepatitis due to obstructive sleep apnea. <i>Gastroenterology</i> , 1995, 109, 1682-1684.	0.6	68
110	Evaluation of amantadine in chronic hepatitis C: a meta-analysis. <i>Journal of Hepatology</i> , 2004, 41, 462-473.	1.8	68
111	Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013, 57, 974-984.	3.6	67
112	Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 387-396.	4.6	67
113	The negative impact of <sc>HBV</sc>/<sc>HCV</sc> coinfection on cirrhosis and its consequences. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1054-1060.	1.9	66
114	Assessing the cost-effectiveness of hepatitis C screening strategies in France. <i>Journal of Hepatology</i> , 2018, 69, 785-792.	1.8	66
115	Liver Transplantation for Alcoholic Liver Disease. <i>Transplantation</i> , 2016, 100, 981-987.	0.5	65
116	Immediate Listing for Liver Transplantation Versus Standard Care for Childâ€Pugh Stage B Alcoholic Cirrhosis. <i>Annals of Internal Medicine</i> , 2009, 150, 153.	2.0	64
117	Shortened treatment duration in treatment-naïve genotype 1 HCV patients with rapid virological response: A meta-analysis. <i>Journal of Hepatology</i> , 2010, 52, 25-31.	1.8	64
118	Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1310-1321.	0.3	64
119	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. <i>Hepatology</i> , 2010, 52, 1201-1207.	3.6	63
120	The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. <i>Nature Communications</i> , 2018, 9, 2092.	5.8	63
121	Prednisone-interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis. <i>Hepatology</i> , 1994, 20, 1390-1398.	3.6	61
122	8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 T	3.8	61
123	Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 416-425.	3.7	60
124	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 T	6.1	59
125	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021, 75, 1026-1033.	1.8	59
126	Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2002, 36, 342-348.	1.8	57



#	ARTICLE	IF	CITATIONS
127	Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). <i>Journal of Hepatology</i> , 2014, 61, 7-14.	1.8	57
128	Relevance of the ISGLS Definition of Posthepatectomy Liver Failure in Early Prediction of Poor Outcome After Liver Resection. <i>Annals of Surgery</i> , 2014, 260, 865-870.	2.1	56
129	Long-term results of percutaneous management for anastomotic biliary stricture after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 394-400.	1.3	55
130	Genome-wide Association Study and Meta-analysis on Alcohol-associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021, 73, 1920-1931.	3.6	54
131	Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 527-537.	2.3	53
132	Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach. <i>Hepatology</i> , 2014, 59, 1471-1481.	3.6	52
133	Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis. <i>Hepatology</i> , 2019, 69, 2180-2195.	3.6	52
134	Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	1.8	52
135	Interferon for interferon naive patients with chronic hepatitis C. <i>The Cochrane Library</i> , 2002, , CD000370.	1.5	50
136	Liver transplantation in patients with alcohol-related liver disease: current status and future directions. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 507-514.	3.7	50
137	Long-term metabolic outcome and quality of life after laparoscopic adjustable gastric banding in obese patients with type 2 diabetes mellitus or impaired fasting glucose. <i>British Journal of Surgery</i> , 2010, 97, 884-891.	0.1	49
138	Assessing bone status in patients awaiting liver transplantation. <i>Joint Bone Spine</i> , 2011, 78, 387-391.	0.8	49
139	Patients with acute liver failure listed for superurgent liver transplantation in France: Reevaluation of the clichyvillejuif criteria. <i>Liver Transplantation</i> , 2015, 21, 512-523.	1.3	49
140	A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso). <i>Journal of Hepatology</i> , 2017, 66, S89.	1.8	49
141	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. <i>American Heart Journal</i> , 2018, 198, 4-17.	1.2	49
142	Corticosteroids for alcoholic hepatitis what's next?. <i>Journal of Hepatology</i> , 2005, 43, 526-533.	1.8	46
143	Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France. <i>Journal of Hepatology</i> , 2008, 49, 175-183.	1.8	46
144	Optimization and robustness of blood tests for liver fibrosis and cirrhosis. <i>Clinical Biochemistry</i> , 2010, 43, 1315-1322.	0.8	42

#	ARTICLE	IF	CITATIONS
145	Combined alcoholic and non-alcoholic steatohepatitis. <i>JHEP Reports</i> , 2020, 2, 100101.	2.6	42
146	NOD2: a potential target for regulating liver injury. <i>Laboratory Investigation</i> , 2008, 88, 318-327.	1.7	41
147	Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 361-369.	0.9	41
148	Randomised clinical trial: enteral nutrition does not improve the long-term outcome of alcoholic cirrhotic patients with jaundice. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1166-1174.	1.9	41
149	Bariatric surgery for curing NASH in the morbidly obese?. <i>Journal of Hepatology</i> , 2013, 58, 1249-1251.	1.8	41
150	Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. <i>Journal of Hepatology</i> , 2012, 57, 39-46.	1.8	40
151	Transient elastography alone and in combination with FibroTest <sup>®</sup> for the diagnosis of hepatic fibrosis in alcoholic liver disease. <i>Liver International</i> , 2017, 37, 1697-1705.	1.9	40
152	Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1516-1526.	1.9	40
153	Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1050-1057.	0.8	39
154	IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, G981-G990.	1.6	37
155	1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL. <i>Journal of Hepatology</i> , 2012, 56, S430-S431.	1.8	37
156	Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 353-362.	1.9	37
157	Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. <i>Nature Communications</i> , 2021, 12, 4560.	5.8	37
158	Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study. <i>Hepatology</i> , 2021, 73, 1945-1955.	3.6	36
159	Histological features predictive of liver fibrosis in chronic hepatitis C infection.. <i>Journal of Clinical Pathology</i> , 1996, 49, 998-1004.	1.0	35
160	Is alcoholic hepatitis an indication for transplantation? Current management and outcomes. <i>Liver Transplantation</i> , 2005, 11, S21-S24.	1.3	35
161	Prevalence of renal abnormalities in chronic HBV infection: The HARPE study. <i>Liver International</i> , 2015, 35, 148-155.	1.9	35
162	IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2020, 72, 1052-1061.	1.8	35

#	ARTICLE	IF	CITATIONS
163	Crushed stents in benign left brachiocephalic vein stenoses. <i>Journal of Vascular Surgery</i> , 2000, 32, 392-396.	0.6	34
164	Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. <i>Clinica Chimica Acta</i> , 2010, 411, 86-91.	0.5	34
165	Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 912-923.	1.8	34
166	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. <i>Hepatology</i> , 2018, 68, 1245-1259.	3.6	33
167	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	1.8	33
168	Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. <i>Gastroenterologie Clinique Et Biologique</i> , 2005, 29, 275-279.	0.9	32
169	Neutrophil Migration During Liver Injury Is Under Nucleotide-Binding Oligomerization Domain 1 Control. <i>Gastroenterology</i> , 2010, 138, 1546-1556.e5.	0.6	32
170	Conversion to sirolimus: A useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient. <i>Liver Transplantation</i> , 2006, 12, 1883-1887.	1.3	31
171	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 4000-4000.	0.8	31
172	Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: A case-control study. <i>Liver Transplantation</i> , 2007, 13, 665-671.	1.3	30
173	1021 GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA (HCC) AND OF ITS TREATMENT WITH SORAFENIB (GIDEON): IMPACT OF LIVER DYSFUNCTION ON SORAFENIB TREATMENT IN EUROPE. <i>Journal of Hepatology</i> , 2012, 56, S399-S400.	1.8	30
174	Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 214-221.	0.7	30
175	Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2006, 70, 154-158.	0.9	29
176	Brief Report: Genetics of Alcoholic Cirrhosisâ€” <sc>G</sc>enom<sc>ALC</sc> Multinational Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 836-842.	1.4	29
177	Liver transplantation for patients with alcoholic hepatitis. <i>Liver International</i> , 2017, 37, 337-339.	1.9	29
178	Transvascular Coil Hooking Procedure to Retrieve an Unraveled Guglielmi Detachable Coil: Technical Note. <i>Neurosurgery</i> , 2002, 50, 912-915.	0.6	28
179	Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 693-9.	1.4	28
180	Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. <i>Liver International</i> , 2014, 34, 907-917.	1.9	28

#	ARTICLE	IF	CITATIONS
181	Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography in patients with renal failure. <i>Transplantation Proceedings</i> , 2000, 32, 432-433.	0.3	27
182	Î-Opioid receptor activation prevents acute hepatic inflammation and cell death. <i>Gut</i> , 2007, 56, 974-981.	6.1	27
183	Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 454-461.	1.9	27
184	Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. <i>Journal of Viral Hepatitis</i> , 2016, 23, 767-779.	1.0	27
185	Impact of a first study of early transplantation in acute alcoholic hepatitis: Results of a nationwide survey in french liver transplantation programs. <i>Liver Transplantation</i> , 2018, 24, 841-844.	1.3	27
186	High-Dose Pegylated Interferon-Î and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial). <i>Gastroenterology</i> , 2011, 141, 119-127.	0.6	26
187	LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*. <i>Journal of Hepatology</i> , 2015, 62, S258-S259.	1.8	26
188	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. <i>American Journal of Gastroenterology</i> , 2021, 116, 106-115.	0.2	25
189	Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences. <i>European Radiology</i> , 1999, 9, 1535-1542.	2.3	24
190	Mycophenolate Mofetil Monotherapy for Severe Side Effects of Calcineurin Inhibitors Following Liver Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 610-613.	2.6	24
191	Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. <i>Hepatology</i> , 2009, 50, 1351-1359.	3.6	24
192	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. <i>Gut</i> , 2017, 66, 1912-1917.	6.1	24
193	Recalibrated MELD and hepatic encephalopathy are prognostic factors in cirrhotic patients with acute variceal bleeding. <i>Liver International</i> , 2018, 38, 469-476.	1.9	24
194	Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 398-405.	0.2	24
195	Interferon for acute hepatitis C. <i>The Cochrane Library</i> , 2001, , CD000369.	1.5	23
196	Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding. <i>Hepatology</i> , 2015, 61, 1024-1032.	3.6	23
197	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. <i>International Journal of Drug Policy</i> , 2019, 72, 61-68.	1.6	23
198	Prevalence of Cholelithiasis According to Alcoholic Liver Disease: A Possible Role of Apolipoproteins AI and AII. <i>Alcoholism: Clinical and Experimental Research</i> , 1995, 19, 75-80.	1.4	22

#	ARTICLE	IF	CITATIONS
199	Tumor necrosis factor soluble receptor p55 and lipid peroxidation in patients with acute alcoholic hepatitis. <i>American Journal of Gastroenterology</i> , 2001, 96, 3361-3367.	0.2	22
200	Mesenteric adenitis and portal vein thrombosis due to <i>Fusobacterium nucleatum</i> . <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1063-1066.	0.8	22
201	Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: A model-based analysis. <i>Journal of Hepatology</i> , 2012, 57, 260-266.	1.8	22
202	Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon.. <i>Gut</i> , 1993, 34, S146-S147.	6.1	21
203	French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. <i>Value in Health</i> , 2018, 21, 1218-1225.	0.1	21
204	Effect of rifaximin on infections, acute and chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-ACH). <i>Liver International</i> , 2022, 42, 1109-1120.	1.9	20
205	Fatal Hemophagocytic Syndrome Related to Human Herpesvirus-6 Reinfection Following Liver Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2008, 40, 3791-3793.	0.3	19
206	Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1326-1334.	0.6	19
207	220 PREDICTIVE FACTORS OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH FULMINANT AND SUBFULMINANT HEPATIC FAILURE: RESULTS FROM A RANDOMIZED CONTROLLED MULTICENTER TRIAL. <i>Journal of Hepatology</i> , 2009, 50, S89-S90.	1.8	18
208	AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendations. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 467-472.	0.7	18
209	LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather. <i>Journal of Hepatology</i> , 2015, 62, S278.	1.8	18
210	Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. <i>Journal of Hepatology</i> , 2019, 70, 831-838.	1.8	18
211	Peroxisome Proliferator-Activated Receptors in HCV-Related Infection. <i>PPAR Research</i> , 2009, 2009, 1-5.	1.1	17
212	Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. <i>Statistical Methods in Medical Research</i> , 2009, 18, 233-252.	0.7	17
213	Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. <i>Gut</i> , 2012, 61, 290-296.	6.1	17
214	Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules. <i>Journal of Hepatology</i> , 2019, 70, 1159-1169.	1.8	17
215	Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage. <i>PLoS ONE</i> , 2019, 14, e0215596.	1.1	17
216	Endpoints and patient stratification in clinical trials for alcoholic hepatitis. <i>Journal of Hepatology</i> , 2019, 70, 314-318.	1.8	17

#	ARTICLE	IF	CITATIONS
217	Early liver transplantation for acute alcoholic hepatitis: We canâ€™t say no. <i>Journal of Hepatology</i> , 2021, 75, 718-722.	1.8	17
218	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. <i>Gut</i> , 2022, 71, 1856-1866.	6.1	17
219	Interest and necessity of combined neuroradiological and neurosurgical treatment in some cases of dural arterio-venous fistulae. <i>Acta Neurochirurgica</i> , 1993, 121, 26-33.	0.9	16
220	Treatment of chronic hepatitis C by interferon for longer duration than six months. <i>Digestive Diseases and Sciences</i> , 1996, 41, 99S-102S.	1.1	16
221	Non-virological factors are drivers of hepatocellular carcinoma in viro-suppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 384-396.	1.0	16
222	2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S466.	1.8	15
223	Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: A modelling approach. <i>Digestive and Liver Disease</i> , 2014, 46, 157-163.	0.4	15
224	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 569-577.	0.8	15
225	A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2315-2323.e6.	2.4	15
226	Hydrocephalus in Guillain-Barré Syndrome. <i>European Neurology</i> , 1991, 31, 426-427.	0.6	14
227	Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. <i>Journal of Viral Hepatitis</i> , 1997, 4, 243-253.	1.0	14
228	Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy. <i>Clinica Chimica Acta</i> , 2013, 415, 63-68.	0.5	14
229	HCV burden in Europe and the possible impact of current treatment. <i>Digestive and Liver Disease</i> , 2013, 45, S314-S317.	0.4	14
230	49 LIFETIME COSTS ATTRIBUTABLE TO CHRONIC HEPATITIS C FROM THE FRENCH HEALTHCARE PERSPECTIVE (ANRS N°12188). <i>Journal of Hepatology</i> , 2013, 58, S21-S22.	1.8	14
231	Alcohol, liver disease, and transplantation. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 175-179.	0.8	14
232	Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 1129-1131.	0.8	13
233	Sequential combination of glucocorticosteroids and alpha interferon versus alpha interferon alone for HBeAg-positive chronic hepatitis B. <i>The Cochrane Library</i> , 2005, , CD000345.	1.5	13
234	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. <i>Future Oncology</i> , 2015, 11, 2553-2562.	1.1	13

#	ARTICLE	IF	CITATIONS
235	Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis. <i>Gut</i> , 2016, 65, 728-729.	6.1	13
236	Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 384-391.	0.8	13
237	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. <i>Alcohol</i> , 2018, 66, 1-7.	0.8	13
238	Extensive portal vein thrombosis related to abdominal trauma. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 314-316.	0.9	12
239	Treatment of severe forms of alcoholic hepatitis: Where are we going?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, S60-S62.	1.4	12
240	Peroxisome Proliferator-Activated Receptors in HBV-Related Infection. <i>PPAR Research</i> , 2009, 2009, 1-6.	1.1	12
241	A French national survey on the use of antibiotic prophylaxis in cirrhotic patients. <i>Liver International</i> , 2013, 33, 389-397.	1.9	12
242	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 393-402.	0.8	12
243	A 2â€log drop in viral load at 1â€fmonth is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study. <i>Journal of Viral Hepatitis</i> , 2009, 16, 500-505.	1.0	11
244	The use of corticosteroids in severe alcohol hepatitis: We need to look beyond this controversy. <i>Journal of Hepatology</i> , 2010, 53, 392-393.	1.8	11
245	Prothrombin index decrease: a useful and reliable marker of extensive fibrosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1057-1059.	0.8	10
246	Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 685-692.	0.9	10
247	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101713.	0.7	10
248	Management of alcoholâ€related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. <i>Liver International</i> , 2022, 42, 1330-1343.	1.9	10
249	Hepatic cirrhosis and kidney transplantation outcome. <i>Transplantation Proceedings</i> , 1997, 29, 2406.	0.3	9
250	75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS. <i>Journal of Hepatology</i> , 2008, 48, S33.	1.8	9
251	29 EARLY TRANSPLANTATION IMPROVES SURVIVAL OF NON-RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A CHALLENGE TO THE 6 MONTH RULE OF ABSTINENCE. <i>Journal of Hepatology</i> , 2010, 52, S13.	1.8	9
252	Management of alcohol dependence in transplant candidates: We are far away from the objective line. <i>Liver Transplantation</i> , 2011, 17, 492-493.	1.3	9

#	ARTICLE	IF	CITATIONS
253	A patient with alcoholic liver failure referred for liver transplantation. <i>Liver Transplantation</i> , 2007, 13, S83-S86.	1.3	8
254	P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER. <i>Journal of Hepatology</i> , 2015, 62, S631-S632.	1.8	8
255	A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases. <i>PLoS ONE</i> , 2016, 11, e0150733.	1.1	8
256	Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?. <i>Journal of Hepatology</i> , 2017, 66, 304-312.	1.8	8
257	Effect of terlipressine (Glypressine®) on hepatorenal syndrome (HRS) in cirrhotic patients: Results of a pilot study. <i>Gastroenterology</i> , 1998, 114, A1214.	0.6	7
258	Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1695-1697.	0.6	7
259	Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study. <i>United European Gastroenterology Journal</i> , 2022, 10, 396-408.	1.6	7
260	Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. , 2002, , CD000345.		6
261	Anticoagulation Therapy May Reverse Biliary Abnormalities Due to Acute Portal Thrombosis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 11-17.	1.1	6
262	21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS. <i>Journal of Hepatology</i> , 2009, 50, S10-S11.	1.8	6
263	47 A MULTICENTRIC, DOUBLE-BLIND, RANDOMISED- CONTROLLED TRIAL (RCT) OF HIGH DOSE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH). <i>Journal of Hepatology</i> , 2009, 50, S21.	1.8	6
264	122 HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH. <i>Journal of Hepatology</i> , 2011, 54, S54.	1.8	6
265	Should patients with alcoholic hepatitis be considered for liver transplantation?. <i>Clinical Liver Disease</i> , 2015, 6, 149-152.	1.0	6
266	Therapeutic management of alcoholic hepatitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, S41-S45.	0.7	6
267	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 677-689.	1.5	6
268	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	1.3	6
269	Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon- $\alpha$ 2b-ribavirin combination therapy. <i>Journal of Medical Virology</i> , 2010, 82, 1640-1646.	2.5	5
270	OC-17 HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach. <i>Digestive and Liver Disease</i> , 2011, 43, S70.	0.4	5



#	ARTICLE	IF	CITATIONS
271	Partial graft recovery following eradication of hepatitis E virus infection after successful islet allograft transplantation. <i>Transplant International</i> , 2011, 24, e13-e15.	0.8	5
272	101 TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUSINFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE. <i>Journal of Hepatology</i> , 2013, 58, S45.	1.8	5
273	The prognostic impact of cirrhosis on patients receiving maintenance haemodialysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 75-83.	1.9	5
274	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 300.	1.3	5
275	Lung Infection Affects Access to Treatment and Short-Term Outcome in Patients With Severe Alcohol-Related Hepatitis Treated With Corticosteroids. <i>American Journal of Gastroenterology</i> , 2022, 117, 1097-1105.	0.2	5
276	Primary sarcoma of the liver and transplantation: a case study and literature review. <i>Rare Tumors</i> , 2009, 1, 93-95.	0.3	4
277	Changes of serum-associated fucosylated glycoproteins and changes in glycosylation of IgA in human cirrhosis. <i>Proteomics - Clinical Applications</i> , 2009, 3, 609-622.	0.8	4
278	Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin. <i>Journal of Hepatology</i> , 2011, 55, 989-995.	1.8	4
279	1357 PENTOXIFYLLINE DOES NOT IMPROVE SHORT-TERM SURVIVAL IN SEVERE ALCOHOLIC HEPATITIS IN COMBINATION WITH CORTICOSTEROIDS: RESULTS OF A RANDOMIZED CONTROLLED TRIAL. <i>Journal of Hepatology</i> , 2012, 56, S533-S534.	1.8	4
280	P0745 : EQ-5D utility index in French patients with chronic hepatitis C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage. <i>Journal of Hepatology</i> , 2015, 62, S605.	1.8	4
281	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101459.	0.7	4
282	Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. <i>JHEP Reports</i> , 2021, 3, 100285.	2.6	4
283	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. <i>Liver Transplantation</i> , 2021, 27, 1382-1391.	1.3	4
284	Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 127-138.	0.4	4
285	950 TOLERANCE AND EFFICACY OF THE MARS SYSTEM IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS NON-RESPONDERS TO STEROIDS: A PILOT STUDY. <i>Journal of Hepatology</i> , 2008, 48, S355-S356.	1.8	3
286	New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort). <i>Journal of Hepatology</i> , 2016, 64, S178.	1.8	3
287	34 PROSPECTIVE SCREENING OF INFECTION IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH STEROIDS: EARLY RESPONSE TO THERAPY IS THE KEY FACTOR. <i>Journal of Hepatology</i> , 2008, 48, S15-S16.	1.8	2
288	1024 EFFICACY AND SAFETY OF THE COMBINATION OF ENTECAVIR (ETV)-TENOFOVIR (TDF) IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A NATIONWIDE, RETROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2010, 52, S396.	1.8	2

#	ARTICLE	IF	CITATIONS
289	1358 A NEW FORMULA OF THE LILLE MODEL USING INR. <i>Journal of Hepatology</i> , 2012, 56, S534.	1.8	2
290	Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2013, 85, 1191-1198.	2.5	2
291	809 IMMEDIATE OR DELAYED TREATMENT INITIATION WITH "PREVIR"-CONTAINING REGIMENS IN HCV-INFECTED NAIVE GENOTYPE 1 (G1) PATIENTS WITHOUT SEVERE FIBROSIS? A COST-EFFECTIVENESS ANALYSIS (ANRS N°12188). <i>Journal of Hepatology</i> , 2013, 58, S331.	1.8	2
292	The Tolerability of SOF/VEL for 12 Weeks in >1,000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis. <i>Journal of Hepatology</i> , 2016, 64, S773-S774.	1.8	2
293	Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort). <i>Journal of Hepatology</i> , 2016, 64, S194-S195.	1.8	2
294	Main drivers of outcome differ between short and long-term in severe alcoholic hepatitis: a prospective study. <i>Journal of Hepatology</i> , 2017, 66, S344-S345.	1.8	2
295	A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients. <i>Liver International</i> , 2021, 41, 91-100.	1.9	2
296	Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. <i>Swiss Medical Weekly</i> , 2021, 151, w20502.	0.8	2
297	Improvement of histological lesions by 18 months therapy with $\alpha$ 2B interferon (IFN 2B) in patients with chronic hepatitis C. A randomized clinical trial. <i>Hepatology</i> , 1993, 18, A90.	3.6	2
298	Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease. <i>Hepatology</i> , 1996, 23, 44-51.	3.6	2
299	ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts. <i>Liver International</i> , 2022, 42, 1386-1400.	1.9	2
300	Sneddon's Syndrome: A Rare Cause of Diffuse Vasculopathy. A Case Report With Review of the Literature. <i>Acta Clinica Belgica</i> , 1990, 45, 107-112.	0.5	1
301	CYTOKINES AND ALCOHOLIC HEPATITIS. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 760-762.	1.4	1
302	Usefulness of routine analysis of ascites fluid at the time of therapeutic paracentesis in asymptomatic cirrhotic out patients. <i>Journal of Hepatology</i> , 2002, 36, 55.	1.8	1
303	Uncovered Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. <i>Gastroenterology</i> , 2006, 130, 1372-1373.	0.6	1
304	220 ACETAMINOPHEN THERAPEUTIC MISADVENTURE: A PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2008, 48, S91.	1.8	1
305	66 PROSPECTIVE EVALUATION OF SORAFENIB (SO) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): DOES CHILD SCORE B INFLUENCE SAFETY?. <i>Journal of Hepatology</i> , 2009, 50, S28.	1.8	1
306	1362 THE AVAILABILITY OF DIRECT ACTING ANTIVIRALS (DAA) IN 2012: A FRENCH MODEL-BASED ANALYSIS OF THE INCREASED NUMBER OF PATIENTS TREATED FOR CHRONIC HCV INFECTION. <i>Journal of Hepatology</i> , 2011, 54, S539-S540.	1.8	1

#	ARTICLE	IF	CITATIONS
307	510 PREVENTION OF LIVER ISCHEMIA/REPERFUSION INJURY BY MODULATING INTESTINAL FLORA: AN ATTRACTIVE APPROACH. <i>Journal of Hepatology</i> , 2011, 54, S209.	1.8	1
308	1034 REAL-WORLD MANAGEMENT OF HCC WITH SORAFENIB AND TACE IN EUROPE FROM GIDEON (GLOBAL) Tj ETQq0 0 0 rgBT /Overl <i>Hepatology</i> , 2012, 56, S404-S405.	1.8	1
309	117 SPONTANEOUS DECREASE IN LIVER INJURY DOES NOT STRONGLY PREDICT EVOLUTION OF PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH CORTICOSTEROIDS. <i>Journal of Hepatology</i> , 2013, 58, S52-S53.	1.8	1
310	O85 SHOULD WE AWAIT INTERFERON-FREE REGIMENS TO TREAT HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS? A COST-EFFECTIVENESS ANALYSIS (ANRS 12188). <i>Journal of Hepatology</i> , 2014, 60, S35.	1.8	1
311	O139 ALCOHOLIC HEPATITIS RESISTANT TO MEDICAL THERAPY IS CHARACTERIZED BY AN ALTERED DIFFERENTIATION OF HEPATIC PROGENITORS UNDER THE INFLUENCE OF EXTRACELLULAR MATRIX. <i>Journal of Hepatology</i> , 2014, 60, S59.	1.8	1
312	P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV mono-infection: Data from the French cohort "ANRS CO22 hepather. <i>Journal of Hepatology</i> , 2015, 62, S488-S489.	1.8	1
313	O017 : Effectiveness of treatment initiation based on fibrosis stage assessed by methods of fibrosis diagnosis in terms of 5-year incidence of morbi-mortality. <i>Journal of Hepatology</i> , 2015, 62, S198.	1.8	1
314	Reply. <i>Gastroenterology</i> , 2016, 150, 284-285.	0.6	1
315	On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1 "6 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies. <i>Journal of Hepatology</i> , 2016, 64, S817.	1.8	1
316	Does Multiorgan Failure Impact Prognosis of Liver Transplantation in Patients with End-Stage Liver Disease? Results of a French Retrospective Multicenter Case-Control Study. <i>Journal of Hepatology</i> , 2016, 64, S537.	1.8	1
317	Comparison of Binary Predictive Scoring Systems of Posthepatectomy Liver Failure. <i>Annals of Surgery</i> , 2017, 265, e57-e58.	2.1	1
318	Liver Transplantation for Severe Alcoholic Hepatitis: Where Are We Now?. <i>Liver Transplantation</i> , 2018, 24, 1327-1328.	1.3	1
319	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
320	Corticosteroids efficacy in severe alcoholic hepatitis (AH): Retrospective analysis of individual data from the American ANF French randomized controlled trials. <i>Gastroenterology</i> , 2000, 118, A972.	0.6	0
321	92 Prediction of mortality in severe alcoholic hepatitis: Validation of lille model and comparison to other prognostic scores. <i>Journal of Hepatology</i> , 2006, 44, S41.	1.8	0
322	698 Histological features associated with fibrosis progression occur in a particular subgroup of heavy drinkers. <i>Journal of Hepatology</i> , 2006, 44, S257.	1.8	0
323	[30] INVOLVEMENT OF NOD SIGNALLING IN HEPATOCYTE AND IMMUNE CELLS DURING HEPATITIS. <i>Journal of Hepatology</i> , 2007, 46, S15.	1.8	0
324	[35] LIVER TRANSPLANTATION (LT) FOR CHOLANGIO-CARCINOMA (CC): LONG-TERM RESULTS IN 42 PATIENTS. <i>Journal of Hepatology</i> , 2007, 46, S17.	1.8	0

#	ARTICLE	IF	CITATIONS
325	[47] THE LONG TERM BENEFITS OF BARIATRIC SURGERY CORRELATED TO INSULIN RESISTANCE: A PROSPECTIVE STUDY WITH 5 YEARS OF FOLLOW UP. <i>Journal of Hepatology</i> , 2007, 46, S23.	1.8	0
326	[153] MYCOPHENOLIC ACID (MPA) AUC(0-12h) IN STABLE LIVER TRANSPLANT PATIENTS TREATED WITH A MONOTHERAPY OF MYCOPHENOLATE MOFETIL (MMF) FOR CALCINEURIN INHIBITORS (CNI) INDUCED NEPHROTOXICITY. <i>Journal of Hepatology</i> , 2007, 46, S68.	1.8	0
327	[582] VIRAL KINETICS CAN PREDICT VIROLOGICAL RESPONSE IN HCV PATIENTS WITH NORMAL ALT TREATED WITH PEGYLATED IFN ALFA-2b AND RIBAVIRIN: A PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2007, 46, S221.	1.8	0
328	PIN4 A MARKOV MODEL TO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMAL TRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY. <i>Value in Health</i> , 2008, 11, A429.	0.1	0
329	32 SERUM PROTEIN PROFILING OF ALCOHOLIC HEPATITIS USING MASS SPECTROMETRY (SELDI-TOF MS) Tj ETQq1 1 0.784314 rgBT <i>Hepatology</i> , 2008, 48, S15.	1.8	0
330	123 EFFICACY AND SAFETY OF AN INTENSIFIED REGIMEN OF PEGYLATED INTERFERON ALFA-2A PLUS RIBAVIRIN IN HCV GENOTYPE 1 NON-RESPONDERS: AN INTERIM ANALYSIS OF THE SYREN TRIAL. <i>Journal of Hepatology</i> , 2009, 50, S50.	1.8	0
331	201 CORTICOSTEROIDS IMPROVE 28-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS: INDIVIDUAL DATA ANALYSIS OF THE LAST 5 RANDOMIZED CONTROLLED TRIALS. <i>Journal of Hepatology</i> , 2009, 50, S82-S83.	1.8	0
332	202 CIRRHOSIS IS A MAJOR PROGNOSTIC FACTOR OF SURVIVAL DIALYZED PATIENTS: THE NEPHRONORD NETWORK STUDY. <i>Journal of Hepatology</i> , 2009, 50, S83.	1.8	0
333	203 TAFI DEFICIENCY AND ENDOTHELIAL CELL ACTIVATION PLAY A KEY ROLE IN COAGULATION DISORDERS OF PATIENTS WITH SEVERE ACUTE-ON-CHRONIC LIVER FAILURE TREATED BY MARSÂ® SYSTEM. <i>Journal of Hepatology</i> , 2009, 50, S83.	1.8	0
334	214 PREGNANCY IN WOMEN WITH PORTAL VEIN CAVERNOMA (PVC): MATERNAL AND FOETAL MANAGEMENT AND OUTCOME. <i>Journal of Hepatology</i> , 2009, 50, S87.	1.8	0
335	606 ANTI-VIRAL THERAPY IN HAEMODIALYZED HCV PATIENTS: EFFICACY, TOLERANCE AND TREATMENT STRATEGY. <i>Journal of Hepatology</i> , 2009, 50, S223.	1.8	0
336	703 BACTERIAL RECEPTOR NOD1 REGULATES THE NEUTROPHIL MIGRATION MACHINERY DURING LIVER INJURY. <i>Journal of Hepatology</i> , 2009, 50, S258.	1.8	0
337	SclÂ©rothÂ©rapie par entÂ©roscopie de varices jÂ©junales hÂ©morragiques. <i>Acta Endoscopica</i> , 2010, 40, 193-194.	0.0	0
338	1161 A PROSPECTIVE STUDY OF ACETAMINOPHEN THERAPEUTIC MISADVENTURE: DURATION OF INTAKE AND HEAVY DRINKING ARE TWO KEY FACTORS. <i>Journal of Hepatology</i> , 2010, 52, S448-S449.	1.8	0
339	1054 MODERATE AND EXCESSIVE ALCOHOL INTAKE IMPACT TRANSPLANT-FREE SURVIVAL: A LONGITUDINAL STUDY IN HCV CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S408.	1.8	0
340	252 2-LOG DROP IN VIRAL LOAD AT ONE MONTH: A NEW STOPPING RULE IN RELAPSE AND NON-RESPONDERS HCV PATIENTS RE-TREATED WITH PEGYLATED-IFN AND RIBAVIRIN?. <i>Journal of Hepatology</i> , 2010, 52, S106.	1.8	0
341	345 DIAGNOSTIC VALUE OF LIVER INJURY BIOMARKERS, FIBROTEST (FT), STEATOTEST (ST), NASHTEST (NT) IN PATIENTS WITHOUT ADVANCED DISEASE UNDERGOING BARIATRIC SURGERY. <i>Journal of Hepatology</i> , 2010, 52, S144.	1.8	0
342	396 ASSESSMENT OF LIVER STIFFNESS (LS) IN THE RELAPSE OF ALCOHOLIC LIVER DISEASE (RALD) AFTER LIVER TRANSPLANTATION (LT). <i>Journal of Hepatology</i> , 2010, 52, S162-S163.	1.8	0

#	ARTICLE	IF	CITATIONS
343	1163 IMPACT OF HBV AND HCV IN KIDNEY TRANSPLANTED PATIENTS: ACTUALIZATION OF PREVALENCE AND PROGNOSTIC DATA. <i>Journal of Hepatology</i> , 2011, 54, S459-S460.	1.8	0
344	501 PROGNOSTIC SCORES ARE EFFICIENT IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH CORTICOSTEROIDS: COMPARISON OF AVAILABLE MODELS. <i>Journal of Hepatology</i> , 2011, 54, S204-S205.	1.8	0
345	626 ASSESSMENT OF RESPONSE TO SORAFENIB IN HEPATOCELLULAR CARCINOMA: PROGNOSTIC VALUE OF TUMORAL DENSITY AND ARTERIAL ENHANCEMENT MEASUREMENTS IN TARGET LESIONS. <i>Journal of Hepatology</i> , 2011, 54, S254.	1.8	0
346	715 BASELINE GENOTYPE AND HBSAG WERE FOUND TO HAVE SIGNIFICANT ASSOCIATION WITH HBEAG SEROCONVERSION FOLLOWING UP TO 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE TREATMENT. <i>Journal of Hepatology</i> , 2011, 54, S287.	1.8	0
347	855 DIAGNOSTIC VALUE OF BIOMARKERS (FIBROTEST, ACHTEST, STEATOTEST AND NASHTEST) FOR THE PREDICTION OF LIVER INJURY IN 494 PATIENTS WITH SEVERE OBESITY. <i>Journal of Hepatology</i> , 2011, 54, S341.	1.8	0
348	6 BARIATRIC SURGERY AN EFFICIENT TREATMENT FOR PATIENT WITH STEATOHEPATITIS. <i>Journal of Hepatology</i> , 2012, 56, S3.	1.8	0
349	100 BASELINE MODELS HELP IN IDENTIFYING RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A MULTICENTER STUDY ON MORE THAN 600 PATIENTS. <i>Journal of Hepatology</i> , 2012, 56, S44.	1.8	0
350	1316 METABOLIC COMORBIDITIES IN A LARGE FRENCH REAL-LIFE COHORT OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2012, 56, S518-S519.	1.8	0
351	Reply to: "HCV infection, HOMA index and sustained virological response: The step we need to take before moving forward". <i>Journal of Hepatology</i> , 2012, 57, 473.	1.8	0
352	1301 BARIATRIC SURGERY CAN BE PROPOSED TO MORBID OBESE HIGHLY SELECTED WITH COMPENSATED CIRRHOSIS. <i>Journal of Hepatology</i> , 2012, 56, S513.	1.8	0
353	405 HARPE STUDY: PREVALENCE OF RENAL ABNORMALITIES IN CHRONIC HBV INFECTION. <i>Journal of Hepatology</i> , 2013, 58, S166-S167.	1.8	0
354	661 ULTRASONOGRAPHIC (US) SCREENING OF HEPATOCELLULAR CARCINOMA (HCC) IN COMPENSATED CIRRHOSIS DUE TO HEPATITIS C VIRUS (HCV) IMPROVES SURVIVAL: A MODELING APPROACH. <i>Journal of Hepatology</i> , 2013, 58, S269.	1.8	0
355	765 TWELVE-MONTHS ENTECAVIR LONGITUDINAL CHANGES IN LIVER FIBROSIS, ACTIVITY AS PER FibroTest-FibroMax AND LIVER STIFFNESS MEASUREMENTS IN CHRONIC HEPATITIS B. STEATOSIS IMPACT ON FIBROSIS REGRESSION. <i>Journal of Hepatology</i> , 2013, 58, S311-S312.	1.8	0
356	287 ICAM-1 AND VCAM-1 EXPRESSION IN HEPATOCYTE IS REGULATED BY NOD1 PATHWAY. <i>Journal of Hepatology</i> , 2013, 58, S121-S122.	1.8	0
357	1350 GASTRIC BYPASS IS EFFICIENT ON METABOLIC AND LIVER STEATOSIS AFTER LAPAROSCOPIC GASTRIC BANDING RELAPSE. <i>Journal of Hepatology</i> , 2013, 58, S543.	1.8	0
358	868 TREATMENT WITH TELAPREVIR-BASED THERAPY AFTER EXPOSURE TO PEG-IFN/RBV IN THE REALIZE STUDY: RESULTS FROM THE PHASE IIIIB C219 ROLLOVER STUDY. <i>Journal of Hepatology</i> , 2013, 58, S356-S357.	1.8	0
359	Reply. <i>Gastroenterology</i> , 2014, 147, 936-937.	0.6	0
360	P957 FINAL ANALYSIS OF AETIOLOGY/COMORBIDITIES IN EUROPEAN PATIENTS FROM THE GIDEON (GLOBAL) Tj ETQq0 0 0 rgBT /Overl	1.8	0

#	ARTICLE	IF	CITATIONS
361	P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER. Journal of Hepatology, 2015, 62, S630-S631.	1.8	0
362	P1093 : Characterization of acetaminophen therapeutic misadventure: A single centre experience. Journal of Hepatology, 2015, 62, S759-S760.	1.8	0
363	P0150 : Liver cirrhosis is independently associated with mortality in patients with bacterial endocarditis: Results of a case control multicenter study of 202 cases. Journal of Hepatology, 2015, 62, S358.	1.8	0
364	Reply to "Albumin infusion in cirrhotic patients with non-SBP infections: End of the story?" Journal of Hepatology, 2015, 63, 768-769.	1.8	0
365	P1087 : Prediction of death as a continuum of risk of mortality in severe alcoholic hepatitis based on baseline and dynamic models. Journal of Hepatology, 2015, 62, S757-S758.	1.8	0
366	P1266 : Human albumin use in cirrhotic patients in France: Results of the national "Albu-live" survey. Journal of Hepatology, 2015, 62, S833.	1.8	0
367	Su1415 The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis. Gastroenterology, 2016, 150, S1093.	0.6	0
368	Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort). Journal of Hepatology, 2016, 64, S273.	1.8	0
369	Clinical and Social Psychological Profiles of Patients with Chronic Hepatitis C Treated with IFN-Free Regimens in France. Journal of Hepatology, 2016, 64, S468-S469.	1.8	0
370	Cost-Effectiveness and Budget Impact of Interferon-Free Direct-Acting Antiviral (DAA)-Based Regimens for Chronic Hepatitis C Treatment. The French Case. Journal of Hepatology, 2016, 64, S470-S471.	1.8	0
371	The Benefits of Viro-suppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort). Journal of Hepatology, 2016, 64, S655-S656.	1.8	0
372	Transient Elastography and Combination of Fibrotest® and Transient Elastography for Diagnosis of Advanced Fibrosis and Cirrhosis in Patients with Alcoholic Liver Disease: A Prospective Multicenter Cohort Study. Journal of Hepatology, 2016, 64, S718-S719.	1.8	0
373	Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies. Gastroenterology, 2016, 150, S1092-S1093.	0.6	0
374	Whole transcriptome analysis of ductular reaction from patients with alcoholic hepatitis. Similarities to ductular reaction in DDC mouse model. Journal of Hepatology, 2017, 66, S81.	1.8	0
375	Cirrhosis impacts outcome of hemodialyzed patients and should lead to consider spontaneous liver-kidney transplantation. Journal of Hepatology, 2017, 66, S368.	1.8	0
376	Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France. Journal of Hepatology, 2017, 66, S414-S415.	1.8	0
377	Final analysis of European patients from the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study: Baseline characteristics and staging systems.. Journal of Clinical Oncology, 2014, 32, 4088-4088.	0.8	0